Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which ...

Pharmaceutical companies are typically rewarded for their innovation with years of market exclusivity before cheaper generics ...

(Reuters) - Europe's STOXX 600 opened lower on Friday, dragged by technology and healthcare stocks, keeping the index on ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...

Evotec International GmbH has synthesized integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of ulcerative colitis and Crohn’s disease.

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...

Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), to bulk up its drug discovery and development portfolio.

FRANKFURT: Europe’s main stock index logged its best day in six weeks on Monday, with defence stocks in the lead ...

Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...

Evotec surged on Monday as it emerged that private equity firm Triton Partners is considering a takeover bid for the German drug development company after taking a near-10% stake.

Any significant move would also need support from Evotec’s other major shareholders — Novo Holdings A/S, the parent company of drugmaker Novo Nordisk A/S, as well as Abu Dhabi sovereign fund Mubadala ...

Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.